Guest User 5/27/26 Guest User 5/27/26 4M Therapeutics to Present at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting Read More Guest User 4/23/26 Guest User 4/23/26 4M Therapeutics to Present at the Upcoming Society of Biological Psychiatry 2026 Annual Meeting Read More Guest User 9/25/25 Guest User 9/25/25 4M Therapeutics Appoints Edward Scolnick, M.D., as Senior Scientific Advisor Read More Guest User 6/11/25 Guest User 6/11/25 4M Therapeutics Reports Positive Results from 4MT2001 GLP Safety Studies Read More Guest User 4/21/25 Guest User 4/21/25 4M Therapeutics to Present at the Upcoming American Psychological Association and American Society of Clinical Psychopharmacology Annual Meetings Read More Guest User 11/13/24 Guest User 11/13/24 4M Therapeutics Awarded $120,000 Grant from SynGAP Research Fund to Evaluate GSK3β Inhibition in Preclinical SYNGAP1-Related Disorders Research Read More Guest User 10/17/24 Guest User 10/17/24 4M Therapeutics’ Compounds to be Utilized in Research Project Funded by National Institute on Aging Read More Guest User 10/1/24 Guest User 10/1/24 4M Therapeutics Presented Preclinical Data at the 26th Annual Conference of the International Society for Bipolar Disorders Read More Guest User 9/9/24 Guest User 9/9/24 4M Therapeutics Announces Positive Preclinical Data for Lead Asset 4MT2001 Demonstrating Central Nervous System Target Engagement Read More Guest User 5/13/24 Guest User 5/13/24 4M Therapeutics Presented Novel Preclinical Data at SOBP Annual Meeting 2024 Demonstrating Potent Effects of Inhibitors of GSK3β for the Treatment of Bipolar Disorder Read More Guest User 5/2/24 Guest User 5/2/24 4M Therapeutics Announces Formation of Clinical Advisory Board with Experts in Neuropsychiatry and Neurodegeneration Read More Guest User 3/4/24 Guest User 3/4/24 4M Therapeutics Strengthens Executive Leadership Team with Appointment of Kimberly Lee, D.O. as Chief Business Officer Read More Pablo Lapuerta 2/9/24 Pablo Lapuerta 2/9/24 4M Therapeutics CEO Pablo Lapuerta to Speak on "Opportunities for Biomarker Development in Neuroscience" at the 9th Annual Biomarker and Companion Diagnostics Conference Read More Benjamin C. Williams 10/18/23 Benjamin C. Williams 10/18/23 WEBINAR: Developing Innovative Compounds for Psychiatric& Neurological Conditions Read More Benjamin C. Williams 8/28/23 Benjamin C. Williams 8/28/23 4M Therapeutics Inc. Announces Oversubscribed $2.575 Million Financing Round Read More Pablo Lapuerta 1/2/23 Pablo Lapuerta 1/2/23 Andrew A. Nierenberg Joins the 4M Therapeutics Scientific Advisory Board Read More Pablo Lapuerta 7/29/22 Pablo Lapuerta 7/29/22 4M Therapeutics, Inc., Enters Into Strategic Partnership with Vala Sciences, Inc., to Advance the 4MTx Pipeline Read More Pablo Lapuerta 6/30/22 Pablo Lapuerta 6/30/22 4M Therapeutics Inc. Announces New Patent License Agreement Read More Pablo Lapuerta 5/16/22 Pablo Lapuerta 5/16/22 Don Hayden and Lawrence Goldstein join 4M Therapeutics Inc. Board of Directors Read More Pablo Lapuerta 4/11/22 Pablo Lapuerta 4/11/22 4M Therapeutics Files Provisional Patents Read More Older Posts
Guest User 5/27/26 Guest User 5/27/26 4M Therapeutics to Present at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting Read More
Guest User 4/23/26 Guest User 4/23/26 4M Therapeutics to Present at the Upcoming Society of Biological Psychiatry 2026 Annual Meeting Read More
Guest User 9/25/25 Guest User 9/25/25 4M Therapeutics Appoints Edward Scolnick, M.D., as Senior Scientific Advisor Read More
Guest User 6/11/25 Guest User 6/11/25 4M Therapeutics Reports Positive Results from 4MT2001 GLP Safety Studies Read More
Guest User 4/21/25 Guest User 4/21/25 4M Therapeutics to Present at the Upcoming American Psychological Association and American Society of Clinical Psychopharmacology Annual Meetings Read More
Guest User 11/13/24 Guest User 11/13/24 4M Therapeutics Awarded $120,000 Grant from SynGAP Research Fund to Evaluate GSK3β Inhibition in Preclinical SYNGAP1-Related Disorders Research Read More
Guest User 10/17/24 Guest User 10/17/24 4M Therapeutics’ Compounds to be Utilized in Research Project Funded by National Institute on Aging Read More
Guest User 10/1/24 Guest User 10/1/24 4M Therapeutics Presented Preclinical Data at the 26th Annual Conference of the International Society for Bipolar Disorders Read More
Guest User 9/9/24 Guest User 9/9/24 4M Therapeutics Announces Positive Preclinical Data for Lead Asset 4MT2001 Demonstrating Central Nervous System Target Engagement Read More
Guest User 5/13/24 Guest User 5/13/24 4M Therapeutics Presented Novel Preclinical Data at SOBP Annual Meeting 2024 Demonstrating Potent Effects of Inhibitors of GSK3β for the Treatment of Bipolar Disorder Read More
Guest User 5/2/24 Guest User 5/2/24 4M Therapeutics Announces Formation of Clinical Advisory Board with Experts in Neuropsychiatry and Neurodegeneration Read More
Guest User 3/4/24 Guest User 3/4/24 4M Therapeutics Strengthens Executive Leadership Team with Appointment of Kimberly Lee, D.O. as Chief Business Officer Read More
Pablo Lapuerta 2/9/24 Pablo Lapuerta 2/9/24 4M Therapeutics CEO Pablo Lapuerta to Speak on "Opportunities for Biomarker Development in Neuroscience" at the 9th Annual Biomarker and Companion Diagnostics Conference Read More
Benjamin C. Williams 10/18/23 Benjamin C. Williams 10/18/23 WEBINAR: Developing Innovative Compounds for Psychiatric& Neurological Conditions Read More
Benjamin C. Williams 8/28/23 Benjamin C. Williams 8/28/23 4M Therapeutics Inc. Announces Oversubscribed $2.575 Million Financing Round Read More
Pablo Lapuerta 1/2/23 Pablo Lapuerta 1/2/23 Andrew A. Nierenberg Joins the 4M Therapeutics Scientific Advisory Board Read More
Pablo Lapuerta 7/29/22 Pablo Lapuerta 7/29/22 4M Therapeutics, Inc., Enters Into Strategic Partnership with Vala Sciences, Inc., to Advance the 4MTx Pipeline Read More
Pablo Lapuerta 6/30/22 Pablo Lapuerta 6/30/22 4M Therapeutics Inc. Announces New Patent License Agreement Read More
Pablo Lapuerta 5/16/22 Pablo Lapuerta 5/16/22 Don Hayden and Lawrence Goldstein join 4M Therapeutics Inc. Board of Directors Read More
